How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias-Reference-Cited by-同舟云学术

How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias

Published:2019-01-15 Issue:S1 Volume:29 Page:3-7
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Platt Robert W.¹²³^ORCID,Platt Richard⁴^ORCID,Brown Jeffrey S.⁴^ORCID,Henry David A.⁵⁶⁷^ORCID,Klungel Olaf H.⁸⁹^ORCID,Suissa Samy¹²^ORCID

Affiliation:

1. Department of Epidemiology, Biostatistics, and Occupational HealthMcGill University Montreal Canada

2. Centre for Clinical EpidemiologyLady Davis Research Institute of the Jewish General Hospital Montreal Canada

3. Centre for Health Outcomes ResearchResearch Institute of the McGill University Health Centre Montreal Canada

4. Department of Population MedicineHarvard Medical School and Harvard Pilgrim Health Care Institute Boston Massachusetts USA

5. Centre for Research in Evidence‐based practiceBond University Gold Coast Australia

6. Melbourne School of Population and Global HealthUniversity of Melbourne Melbourne Australia

7. Institute for Clinical and Evaluative Sciences Toronto Canada

8. Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical SciencesUtrecht University Utrecht The Netherlands

9. Julius Center for Health Sciences and Primary CareUniversity Medical Center Utrecht Utrecht The Netherlands

Funder

Canadian Institutes of Health Research

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4722

Reference30 articles.

1. Pharmacoepidemiology

2. 21st CenturyCures Act.https://www.congress.gov/114/plaws/publ255/PLAW‐ 114publ255.pdf. Accessed November 3 2018

3. EMAScientific guidance on post‐authorisation efficacy studies.https://www.ema.europa.eu/documents/scientific‐guideline/scientific‐guidance‐post‐authorisation‐efficacy‐studies‐first‐version_en.pdf. Accessed November 3 2018

4. PatilP PengRD LeekJ.A statistical definition for reproducibility and replicability. bioRxiv.2016.

5. Are Mortality Differences Detected by Administrative Data Reliable and Actionable?

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harmonizing Norwegian registries onto OMOP common data model: Mapping challenges and opportunities for pregnancy and COVID-19 research;International Journal of Medical Informatics;2024-11

2. Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review;Pharmacoepidemiology and Drug Safety;2024-05

3. Innovations in pharmacovigilance studies of medicines in older people;British Journal of Clinical Pharmacology;2024-03-26

4. Association between long-term use of calcium channel blockers (CCB) and the risk of breast cancer: a retrospective longitudinal observational study protocol;BMJ Open;2024-03

5. Standardizing to specific target populations in distributed networks and multisite pharmacoepidemiologic studies;American Journal of Epidemiology;2024-02-27